

Thermo Fisher to acquire viral vector manufacturing firm

25 March 2019 | News

Significantly expands capabilities to support high-growth gene and cell therapy market



Thermo Fisher Scientific Inc., the world leader in serving science, and Brammer Bio, a leader in viral vector manufacturing for gene and cell therapies, has announced that they have entered into a definitive agreement under which Thermo Fisher will acquire Brammer Bio for approximately \$1.7 billion in cash.

Brammer Bio is a leading viral vector contract development and manufacturing organization (CDMO), enabling biopharma customers to deliver breakthrough medicines to patients by unleashing the potential of gene therapies and gene-modified cell therapies. The business has nearly 600 employees at primary locations in Massachusetts and Florida.

The transaction, which is expected to be completed by the end of the second quarter of 2019, is subject to customary closing conditions, including regulatory approvals. Upon completion, Brammer Bio will become part of Thermo Fisher's pharma services business within its Laboratory Products and Services Segment.